查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1953439

月经症候群 (PMS) 和月经健康补充剂市场 - 全球产业规模、份额、趋势、机会和预测：按产品类型、适应症、剂型、最终用途、地区和竞争格局划分，2021-2031 年

Premenstrual Syndrome and Menstrual Health Supplements Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented Product Type, By Indication, By Formulation, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球月经症候群 (PMS) 和月经健康补充剂市场预计将从 2025 年的 214.5 亿美元增长到 2031 年的 296.8 亿美元，复合年增长率达到 5.56%。

这些膳食补充剂通常由特殊的营养保健品组合药物构成，包含维生素、矿物质和植物萃取物，旨在缓解与月经週期相关的生理和心理症状。市场成长的主要驱动力是全球月经症候群发生率的上升，以及消费者健康管理方式转向预防性、非药物疗法的根本性转变。与新剂型等暂时性的市场趋势不同，这些驱动因素代表着对长期生殖健康的结构性承诺，以及对传统止痛药天然替代品的持续需求。

市场概览
预测期 2027-2031
市场规模：2025年 214.5亿美元
市场规模：2031年 296.8亿美元
复合年增长率：2026-2031年 5.56%
成长最快的细分市场 月经症候群（PMS）
最大的市场 北美洲

市场扩张的一大障碍是复杂的法规环境。由于缺乏统一的健康声明支持标准，如果製造商没有严格的临床证据，就无法宣传特定的疗效。这种全球监管的不一致性常常为产品分销和行销合规带来挑战。例如，人们越来越依赖针对特定症状的成分。负责任营养委员会 (CRN) 的报告显示，到 2024 年，镁（一种用于缓解月经和情绪波动的关键营养素）在膳食补充剂消费者中的使用量增加了 23%。

市场驱动因素

意识提升以及围绕月经健康的污名化现象的消除，正在从根本上改变市场动态，鼓励人们公开讨论那些过去被视为正常或被忽视的症状。这种文化演变正将月经护理的重点从简单的卫生护理转向全面的管理，并鼓励女性积极寻求营养解决方案以维持健康和工作效率。健康素养的提高与产品消费之间的直接关联日益明显，消费者正从一般保健产品转向针对特定症状的产品。例如，The Vitamin Shoppe 于 2024 年 6 月发布的《2024 年健康与保健趋势报告》显示，专为经月经症候群 (PMS) 设计的配方产品的销量较上年度增长了 12%，表明消费者对针对特定症状的管理需求日益增长。

同时，消费者对天然、有机和植物来源成分的偏好日益增长，推动了洁净标示膳食补充剂的发展，因为他们逐渐远离合成药物。这一趋势青睐植物萃取物和生物利用度高的矿物质，与传统止痛药相比，这些成分被视为更安全的长期荷尔蒙调节替代品。根据Holland & Barrett于2024年11月发布的《2025年健康趋势报告》，镁甘氨酸（一种因其在月经温和吸收和肌肉放鬆功效而备受推崇的矿物质）的在线搜寻量激增180%。这种对高品质非药物替代品的需求正在推动整个品类的扩张。 Haleon于2025年2月发布的《2024年全年业绩报告》显示，其维生素、矿物质和膳食补充剂部门的有机收入增加了7.6%。

市场挑战

复杂的法规环境和不一致的健康声明验证标准，对全球月经症候群 (PMS) 和月经健康补充剂市场的扩张构成了重大障碍。膳食补充剂法规的显着区域差异意味着製造商在产品配方和行销传播的标准化方面面临巨大挑战。在许多司法管辖区，法律禁止产品在未经广泛且昂贵的临床检验的情况下，做出诸如缓解月经或减轻荷尔蒙引起的情绪波动等特定疗效声明。这导致品牌无法充分向消费者宣传植物来源和营养配方产品的有效性，最终限制了销售量和市场渗透率。

在消费者对特殊功能性成分日益增长的兴趣下，这种监管限制尤其具有挑战性。根据责任营养委员会 (CRN) 2024 年的一份报告，睡茄（一种常用于缓解压力和调节情绪的植物萃取物）的使用率已达到膳食补充剂使用者的 8%。儘管消费者对这类天然替代品的需求显而易见，但严格的证据规则限制了製造商明确宣称其产品具有与月经症候群 (PMS) 相关的直接功效，从而阻碍了产品差异化。因此，市场难以将消费者对这类成分日益增长的认知转化为更广泛的品类增长，因为消费者往往不愿意购买那些被迫做出模糊或淡化健康声明的产品。

市场趋势

週期性营养补充的兴起正在推动产品开发的根本性转变。消费者越来越倾向于选择针对卵泡期、排卵期、黄体期和月经期的特定阶段营养方案，而非传统的综合维他命。这种趋势超越了简单的营养补充，推动了对先进的28天套装的需求，这些套装能够根据实时激素变化同步释放营养成分，例如在黄体期补充镁以改善情绪，或在月经补充铁。从被动因应症状到主动优化荷尔蒙水平的转变，也反映在消费者对数位化参与度的提升。例如，《The Drum》在2025年1月发表了一篇题为《为什么女性会转向TikTok寻求月经建议？品牌在哪里？ 》的报导，其中指出Google趋势数据显示，消费者对週期同步营养补充的兴趣同比增长了124%，这表明品牌拥有巨大的机会去教育和吸引这一信息灵通的群体。

同时，人工智慧驱动的个人化营养计画的引入正在改变经营模式，透过数据驱动的客製化将偶尔购买者转化为长期定期订阅。演算法测试评估个人的症状模式和生物特征数据，使製造商能够针对特定的生殖健康目标（例如更年期过渡或减轻月经症候群 (PMS) 的严重程度）定制精准的每日营养包，从而提升客户价值感知和客户维繫。这种技术与健康的融合正在为领导企业带来显着的经济效益。根据 NutraIngredients 2024 年 7 月发表的一篇报导《联合利华探讨健康业务的爆炸式增长》，人工智慧等新兴工具的整合，加上对女性健康领域的战略关注，使得该公司健康与福祉部门的基础销售额增长了 20%。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球月经症候群 (PMS) 和月经健康补充剂市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依适应症（围绝经期、经前症候群）
    • 按剂型（胶囊/锭剂、粉末、软胶囊、其他）
    • 依最终用途（药局/药局、线上销售管道、销售管道、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

6. 北美月经症候群 (PMS) 和月经健康补充剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国家分析
    • 我们
    • 加拿大
    • 墨西哥

7. 欧洲月经症候群 (PMS) 和月经健康补充剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国家分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

8. 亚太地区月经症候群（PMS）和月经健康补充剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

9. 中东和非洲月经症候群 (PMS) 及月经健康补充品市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东和非洲：国家分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

10. 南美洲月经症候群 (PMS) 与月经健康补充剂市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国家分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 司机
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 最新进展

13. 全球月经症候群 (PMS) 和月经健康补充剂市场：SWOT 分析

第十四章 波特五力分析

  • 产业竞争
  • 新进入者的可能性
  • 供应商电力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Herbalife International of America, Inc.
  • Nature's Bounty
  • Amway Corp.
  • GNC Holdings, LLC
  • USANA Health Sciences, Inc
  • GlaxoSmithKline Plc
  • MetP Pharma AG
  • Archer-Daniels-Midland Company
  • Power Gummies
  • Looni

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24094

The Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market is projected to expand from USD 21.45 Billion in 2025 to USD 29.68 Billion by 2031, achieving a compound annual growth rate (CAGR) of 5.56%. These supplements typically consist of specialized nutraceutical formulations containing vitamins, minerals, and botanical extracts intended to alleviate the physiological and psychological symptoms linked to the menstrual cycle. The market's growth is primarily sustained by the increasing global incidence of premenstrual disorders and a fundamental consumer shift toward preventive, non-pharmaceutical health management; unlike fleeting market trends such as new delivery formats, these drivers indicate a structural commitment to long-term reproductive wellness and a persistent demand for natural substitutes to traditional pain medications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 21.45 Billion
Market Size 2031USD 29.68 Billion
CAGR 2026-20315.56%
Fastest Growing SegmentPMS (Premenstrual Syndrome)
Largest MarketNorth America

A major obstacle hindering wider market scalability is the intricate regulatory environment, where inconsistent standards for substantiating health claims prevent manufacturers from advertising specific therapeutic benefits without rigorous clinical proof. This absence of global regulatory alignment frequently creates difficulties in product distribution and marketing compliance. Illustrating the increasing dependence on ingredients that target specific symptoms, the Council for Responsible Nutrition reported in 2024 that the usage of magnesium, a critical nutrient employed to manage menstrual cramps and mood swings, increased to 23 percent among supplement consumers.

Market Driver

The growing consumer awareness and the destigmatization surrounding menstrual health are fundamentally transforming market dynamics by fostering open discussions about symptoms that were historically normalized or ignored. This cultural evolution has shifted the focus of menstrual care from simple hygiene to comprehensive management, encouraging women to proactively seek nutraceutical solutions to maintain their well-being and productivity. A direct link is emerging between this increased health literacy and product consumption, as buyers graduate from general wellness items to targeted remedies; for instance, The Vitamin Shoppe's 'Health & Wellness Trend Report 2024' from June 2024 noted a 12 percent increase in sales of specialized PMS formulas over the previous year, underscoring the rising demand for symptom-specific management.

At the same time, a growing preference for natural, organic, and plant-based ingredients is propelling the development of clean-label supplements as consumers move away from synthetic pharmaceuticals. This trend prioritizes botanical extracts and bioavailable minerals, which are viewed as safer alternatives for long-term hormonal regulation compared to conventional pain relievers. According to Holland & Barrett's 'Wellness Trends Report 2025' released in November 2024, online searches for Magnesium Glycinate-a mineral form valued for its gentle absorption and muscle-relaxing effects during menstruation-surged by 180 percent. This appetite for high-quality, non-pharmacological choices is fueling broader category expansion, as evidenced by Haleon's '2024 Full year results' from February 2025, which reported a 7.6 percent growth in organic revenue for their Vitamins, Minerals and Supplements division.

Market Challenge

The intricate regulatory environment and inconsistent standards regarding the substantiation of health claims create a significant barrier to scalability within the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market. Since dietary supplement regulations vary widely across different regions, manufacturers encounter major challenges in standardizing product formulations and marketing communications. In numerous jurisdictions, companies are legally prohibited from making specific therapeutic assertions-such as claiming a product alleviates menstrual cramps or reduces hormonal mood swings-without expensive and extensive clinical validation, which prevents brands from fully conveying the efficacy of their botanical and nutrient-based formulas to consumers and ultimately suppresses sales volume and market penetration.

This regulatory constraint is especially restrictive given the growing consumer interest in specialized functional ingredients. As reported by the Council for Responsible Nutrition in 2024, the usage of ashwagandha, a botanical extract frequently used for stress and mood regulation, reached 8 percent among supplement users. Although consumer demand for such natural alternatives is clear, the inability of manufacturers to explicitly label these products with their direct PMS-related benefits due to rigorous substantiation rules hinders product differentiation; consequently, the market faces difficulties in translating this rising ingredient awareness into broader category growth, as consumers often remain reluctant to buy products that are forced to carry vague or diluted health claims.

Market Trends

The widespread adoption of cycle-syncing supplement regimens is fundamentally changing product development, with consumers increasingly moving away from static multivitamins in favor of phase-specific formulations designed for the follicular, ovulatory, luteal, and menstrual phases. This trend goes beyond simple nutrient replenishment, fostering demand for sophisticated 28-day kits that synchronize ingredient release profiles-such as increasing magnesium during the luteal phase for mood support or supplementing iron during menstruation-with real-time hormonal changes. This transition from reactive symptom management to proactive hormonal optimization is highlighted by rising digital engagement; specifically, The Drum reported in January 2025, in the article 'Why are women forced to turn to TikTok for menstrual advice? Where are the brands?', that Google Trends data showed a 124 percent year-on-year increase in consumer interest regarding cycle syncing, indicating a substantial opportunity for brands to educate and engage this informed demographic.

Concurrently, the incorporation of AI-driven personalized nutrition plans is transforming business models by turning sporadic buyers into long-term subscribers through data-based customization. By employing algorithmic quizzes to assess individual symptom patterns and biometric data, manufacturers can now assemble high-precision daily packs that target specific reproductive health objectives, such as managing the perimenopausal transition or PMS severity, thereby increasing perceived value and customer retention. This convergence of technology and health is generating significant financial returns for leading industry players; according to NutraIngredients in July 2024, in the article 'Unilever talks explosive growth of its wellness business', the integration of emerging tools like artificial intelligence combined with a strategic emphasis on women's health categories drove a 20 percent underlying sales growth for the company's Health & Wellbeing Collective.

Key Market Players

  • Herbalife International of America, Inc.
  • Nature's Bounty
  • Amway Corp.
  • GNC Holdings, LLC
  • USANA Health Sciences, Inc
  • GlaxoSmithKline Plc
  • MetP Pharma AG
  • Archer-Daniels-Midland Company
  • Power Gummies
  • Looni

Report Scope

In this report, the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Indication

  • Perimenopause
  • PMS

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Formulation

  • Capsules/Tablets
  • Powder
  • Softgels
  • Other

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By End Use

  • Pharmacies/Drug Stores
  • Online Sales Channel
  • Direct Sales Channel
  • Others

Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market.

Available Customizations:

Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Indication (Perimenopause, PMS)
    • 5.2.2. By Formulation (Capsules/Tablets, Powder, Softgels, Other)
    • 5.2.3. By End Use (Pharmacies/Drug Stores, Online Sales Channel, Direct Sales Channel, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication
    • 6.2.2. By Formulation
    • 6.2.3. By End Use
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Indication
        • 6.3.1.2.2. By Formulation
        • 6.3.1.2.3. By End Use
    • 6.3.2. Canada Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Indication
        • 6.3.2.2.2. By Formulation
        • 6.3.2.2.3. By End Use
    • 6.3.3. Mexico Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Indication
        • 6.3.3.2.2. By Formulation
        • 6.3.3.2.3. By End Use

7. Europe Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Formulation
    • 7.2.3. By End Use
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Indication
        • 7.3.1.2.2. By Formulation
        • 7.3.1.2.3. By End Use
    • 7.3.2. France Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Indication
        • 7.3.2.2.2. By Formulation
        • 7.3.2.2.3. By End Use
    • 7.3.3. United Kingdom Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Indication
        • 7.3.3.2.2. By Formulation
        • 7.3.3.2.3. By End Use
    • 7.3.4. Italy Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Indication
        • 7.3.4.2.2. By Formulation
        • 7.3.4.2.3. By End Use
    • 7.3.5. Spain Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Indication
        • 7.3.5.2.2. By Formulation
        • 7.3.5.2.3. By End Use

8. Asia Pacific Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Formulation
    • 8.2.3. By End Use
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Indication
        • 8.3.1.2.2. By Formulation
        • 8.3.1.2.3. By End Use
    • 8.3.2. India Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Indication
        • 8.3.2.2.2. By Formulation
        • 8.3.2.2.3. By End Use
    • 8.3.3. Japan Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Indication
        • 8.3.3.2.2. By Formulation
        • 8.3.3.2.3. By End Use
    • 8.3.4. South Korea Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Indication
        • 8.3.4.2.2. By Formulation
        • 8.3.4.2.3. By End Use
    • 8.3.5. Australia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Indication
        • 8.3.5.2.2. By Formulation
        • 8.3.5.2.3. By End Use

9. Middle East & Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Formulation
    • 9.2.3. By End Use
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Indication
        • 9.3.1.2.2. By Formulation
        • 9.3.1.2.3. By End Use
    • 9.3.2. UAE Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Indication
        • 9.3.2.2.2. By Formulation
        • 9.3.2.2.3. By End Use
    • 9.3.3. South Africa Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Indication
        • 9.3.3.2.2. By Formulation
        • 9.3.3.2.3. By End Use

10. South America Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Formulation
    • 10.2.3. By End Use
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Indication
        • 10.3.1.2.2. By Formulation
        • 10.3.1.2.3. By End Use
    • 10.3.2. Colombia Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Indication
        • 10.3.2.2.2. By Formulation
        • 10.3.2.2.3. By End Use
    • 10.3.3. Argentina Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Indication
        • 10.3.3.2.2. By Formulation
        • 10.3.3.2.3. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Premenstrual Syndrome (PMS) and Menstrual Health Supplements Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Herbalife International of America, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Nature's Bounty
  • 15.3. Amway Corp.
  • 15.4. GNC Holdings, LLC
  • 15.5. USANA Health Sciences, Inc
  • 15.6. GlaxoSmithKline Plc
  • 15.7. MetP Pharma AG
  • 15.8. Archer-Daniels-Midland Company
  • 15.9. Power Gummies
  • 15.10. Looni

16. Strategic Recommendations

17. About Us & Disclaimer